-
B.C. company receives NRC funding for HIV/AIDS treatment
Vancouver-based iCo Therapeutics, a drug reprofiling company, has been awarded a $1.1 million non-repayable financial contribution from the National Research Council of Canada to support iCo’s Oral Amphotericin B (Amp B) delivery system as novel treatment for patients with Human Immunodeficiency Virus (HIV).